Search clinical trials for: LHRH Agonist

Total 14286 results

Mayo Clinic

Recruiting

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment Prostate Cancer

Prostate Adenocarcinoma | Oligometastatic Prostate Carcinoma

United States
University of Washington
Breast Cancer Research Foundation

Not yet recruiting

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic HER2-Negative Breast Carcinoma | Metastatic Hormone Receptor-Positive Breast Carcinoma | Locally Advanced Unresectable HER2-Negative Breast Carcinoma | Locally Advanced Unresectable Hormone Receptor-Positive...

United States
Hoffmann-La Roche

Recruiting

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

Belgium, Korea, Republic of, United States, Canada, China, Italy, France, Brazil, Australia, Argentina, Hong Kong, Portugal, Spain, Taiwan, Costa Rica, Israel, Thailand, Germany, New Zealand, Poland, Chile, Colombia, Guatemala, Hungary, Indi...
Dana-Farber Cancer Institute
Eli Lilly and Company

Recruiting

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

Breast Cancer | Early-stage Breast Cancer | High Risk Breast Carcinoma

United States
Fudan University

Recruiting

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Breast Cancer

China
Rana McKay, MD
University of California, San Diego; AstraZeneca

Recruiting

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations (NePtune)

Prostate Cancer | BRCA1 Mutation | BRCA2 Mutation | Prostatic Adenocarcinoma | High-Risk Cancer

United States
Genentech, Inc.

Recruiting

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

Korea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

Locally Advanced or Metastatic Breast Cancer

France, Belgium, United States, Korea, Republic of, Taiwan, Brazil, China, Italy, Argentina, Jordan, Mexico, Germany, Portugal, Spain, Thailand, Turkey, United Kingdom, Kenya, Hungary, Poland, Colombia, India, Oman, Uganda, United Arab... and more
AstraZeneca

Recruiting

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (SERENA-6)

ER-Positive HER2-Negative Breast Cancer

United States, Israel, Spain, Korea, Republic of, Italy, Poland, Belgium, Norway, Bulgaria, France, Germany, United Kingdom, Japan, Taiwan, Canada, Hungary, Australia, Austria, Portugal, Turkey, Russian Federation, Slovakia, Switzer...
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

Early Breast Cancer

United States, France, Korea, Republic of, Spain, China, Italy, Taiwan, Sweden, Czechia, Hungary, Japan, Greece, Ukraine, Australia, Brazil, Canada, Mexico, Belgium, Argentina, Chile, Serbia, Colombia, Ireland, Hong Kong, Austria, North Macedonia and more
Dana-Farber Cancer Institute
Genentech, Inc.

Recruiting

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (ADEPT)

Breast Cancer | HER2-positive Breast Cancer | Hormone Receptor Positive Breast Cancer | Invasive Carcinoma of the Breast | Node Negative Breast Cancer | Micrometastasis Breast Cancer

United States
Janssen Pharmaceutica N.V., Belgium

Recruiting

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (PRIMORDIUM)

Prostatic Neoplasms

Italy, Russian Federation, Brazil, Portugal, Belgium, Spain, United States, Austria, Hungary, Turkey, Germany, Australia, Poland, Mexico, Finland, Slovakia, Lebanon, Czechia, Denmark, Jordan, Sweden
UNICANCER
Janssen Pharmaceutica

Recruiting

Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy (CARLHA-2)

Prostate Cancer

France
Cancer Research Antwerp
Janssen Pharmaceutica

Recruiting

Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP (SAVE)

Cancer of Prostate

Belgium
University of Chicago

Recruiting

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

Breast Cancer | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III

Nigeria
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Recruiting

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma

United States
M.D. Anderson Cancer Center
Pfizer

Active, not recruiting

Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy

Prostate Cancer

United States
Hoffmann-La Roche
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (BOUQUET)

Ovarian Cancer

United States, Korea, Republic of, France, Germany, Spain, Italy, Canada, Russian Federation, United Kingdom, Turkey, Australia, Czechia, Switzerland
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology; Cancer and Leukemia Group B

Active, not recruiting

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

Prostate Cancer

United States, Canada, China, Israel
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

United States, Italy, Korea, Republic of, Canada, Germany, United Kingdom, Australia, Belgium, Brazil, China, Denmark, France, Hong Kong, Portugal, Spain, Taiwan, Turkey, Japan, Argentina, Mexico, Israel, Poland, Russian Federation, A... and more
Eli Lilly and Company
Bayer

Active, not recruiting

Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

Prostatic Neoplasms

Spain, Germany, United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Sanofi

Completed

Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer

Prostate Cancer

United States
AstraZeneca

Active, not recruiting

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (SERENA-4)

ER-Positive HER2-Negative Breast Cancer

Austria, Belgium, France, Germany, Italy, United Kingdom, United States, Canada, India, Taiwan, Russian Federation, Korea, Republic of, Hungary, Japan, Mexico, Turkey, China, Malaysia, Spain, Czechia, Portugal, Poland, Norway, Bulgaria, Slovaki... and more
Genentech, Inc.

Active, not recruiting

A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

Breast Cancer

United States, Spain, Korea, Republic of, Australia, United Kingdom
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

United States, Korea, Republic of, China, Poland, Taiwan, Turkey, United Kingdom, Australia, Argentina, Germany, Singapore, Thailand, Israel, Russian Federation, Ukraine, Brazil, South Africa
Pfizer

Active, not recruiting

A Study of PF-06873600 in People With Cancer

HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer

United States, Japan, Canada, Russian Federation, Bulgaria, Ukraine
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Active, not recruiting

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Prostate Cancer

United States, Canada
Fondazione Sandro Pitigliani
Novartis

Active, not recruiting

FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer (FACILE)

Breast Cancer

Italy
Dana-Farber Cancer Institute
Janssen Scientific Affairs, LLC

Active, not recruiting

Conventional ADT w/ or w/Out Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT

Prostate Cancer

United States
Spanish Breast Cancer Research Group
Eli Lilly and Company

Active, not recruiting

Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients (CARABELA)

Early Breast Cancer

Spain
Yale University
Johns Hopkins University; Eunice Kennedy Shriver National Institute of Child... and other collaborators

Completed

Pharmacokinetics and Hepatic Safety of EGCG

Uterine Fibroids

United States
CHU de Quebec-Universite Laval
GlaxoSmithKline

Completed

Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy

Lower Urinary Tract Symptoms | Erectile Dysfunction | Prostate Cancer

Canada
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Active, not recruiting

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Prostate Cancer

United States, Canada
iOMEDICO AG
Pfizer

Completed

Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant (INGE-B)

Breast Cancer | Hormone Receptor Positive Tumor | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Germany
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical... and other collaborators

Active, not recruiting

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

Prostate Cancer

United States, Canada
M.D. Anderson Cancer Center

Completed

Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer

Prostate Adenocarcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8

United States
Ajjai Alva, MD
Hoosier Cancer Research Network; Bayer Healthcare Pharmaceuticals, Inc./Bayer...

Terminated

Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases

Prostate Cancer | Bone Metastases | Prostate Neoplasms

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Completed

Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer

Prostate Cancer

United States, Canada
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Prostate Cancer

United States, Canada
Genentech, Inc.

Terminated

A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Breast Cancer

United States, Korea, Republic of, Spain, Netherlands
Pantarhei Oncology B.V.

Completed

Evaluation of Effects of Estetrol on Testosterone Suppression and Quality of Life in Prostate Cancer Patients Treated With an LHRH Agonist.

Prostatic Neoplasm

Netherlands
Lawson Health Research Institute

Completed

Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer - Protocol 2 (FASTR-2)

Prostate Cancer

Canada
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer

Prostate Cancer

United States, Canada
European Organisation for Research and Treatment...

Withdrawn

Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer (ARN-509)

Prostate Cancer
Juravinski Cancer Center
Sanofi

Unknown

Prostate Boost Irradiation With Stereotactic Body RT (SBRT) (PBS)

Prostate Cancer

Canada
Aragon Pharmaceuticals, Inc.

Completed

The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer

Prostate Cancer

United States
M.D. Anderson Cancer Center
Medivation, Inc.; Janssen Services, LLC

Completed

Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide

Prostate Cancer

United States
Azienda Ospedaliero-Universitaria Careggi

Unknown

CIRCULATING MICRO-RNA (miRNA) AND AR-V7 MUTATIONAL STATUS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC): PRIMERA+ STUDY (PROSTATE CANCER INNOVATING MARKERS OF EXPECTED RESPONSE TO AGONIST LHRH+ ANDROGEN RECEPTOR INHIBITION (PRIMERA)

D011471 | D064129 | D035683 | D009360 | D014408

Italy
M.D. Anderson Cancer Center

Completed

Melanoma Vaccine With Peptides and Leuprolide

Melanoma

United States
Ferring Pharmaceuticals

Completed

Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists. (ProComD)

Advanced Prostate Cancer

Germany

Search clinical trials for: LHRH Agonist

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations